Drug Profile

Duvelisib - Secura Bio

Alternative Names: ABBV-954; COPIKTRA; INK-1197; IPI-145; VS-0145; YHI-1702

Latest Information Update: 25 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Intellikine
Developer AbbVie; CSPC Pharmaceutical Group; Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Secura Bio; Verastem Oncology; Yakult Honsha
Class Anti-inflammatories; Antiasthmatics; Antineoplastics; Antirheumatics; Isoquinolines; Purines; Small molecules
Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - T-cell lymphoma; Chronic lymphocytic leukaemia; Peripheral T-cell lymphoma; Follicular lymphoma
New Molecular Entity Yes

Marketed Chronic lymphocytic leukaemia
Registered Follicular lymphoma
Phase III Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
Phase II COVID 2019 infections; Haematological malignancies; Squamous cell cancer
Phase I/II Malignant melanoma; Richter's syndrome
No development reported Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours; T-cell lymphoma
Discontinued Allergic asthma; Rheumatoid arthritis

17 Dec 2025 The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) added Duvelisib as a Category 2A treatment option for mycosis fungoides and Sézary syndrome (MFSS)
07 Dec 2025 Updated efficacy and adverse event data from the phase II PRIMO trial in T-cell lymphoma released by Secura Bio
06 Dec 2025 Efficacy and adverse event data from the phase II PRIMO trial in T-cell lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com